This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thorpe, P. E. Search for Related Content PubMed PubMed Citation Articles by Thorpe, P. E. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Small Molecules Clinical Research: Clinical Trials

Vascular Targeting Agents as Cancer Therapeutics

Department of Pharmacology and Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas

Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood vessels of tumors. Unlike antiangiogenic drugs that inhibit the formation of new vessels, VTAs occlude the pre-existing blood vessels of tumors to cause tumor cell death from ischemia and extensive hemorrhagic necrosis. Tumor selectivity is conferred by differences in the pathophysiology of tumor versus normal tissue vessels (e.g., increased proliferation and fragility, and up-regulated proteins). VTAs can kill indirectly the tumor cells that are resistant to conventional antiproliferative cancer therapies, i.e., cells in areas distant from blood vessels where drug penetration is poor, and hypoxia can lead to radiation and drug resistance. VTAs are expected to show the greatest therapeutic benefit as part of combined modality regimens. Preclinical studies have shown VTA-induced enhancement of the effects of conventional chemotherapeutic agents, radiation, hyperthermia, radioimmunotherapy, and antiangiogenic agents. There are broadly two types of VTAs, small molecules and ligand-based, which are grouped together, because they both cause acute vascular shutdown in tumors leading to massive necrosis. The small molecules include the microtubulin destabilizing drugs, combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and Oxi 4503, and the flavonoid, DMXAA. Ligand-based VTAs use antibodies, peptides, or growth factors that bind selectively to tumor versus normal vessels to target tumors with agents that occlude blood vessels. The ligand-based VTAs include fusion proteins (e.g., vascular endothelial growth factor linked to the plant toxin gelonin), immunotoxins (e.g., monoclonal antibodies to endoglin conjugated to ricin A), antibodies linked to cytokines, liposomally encapsulated drugs, and gene therapy approaches. Combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and DMXAA are undergoing clinical evaluation. Phase I monotherapy studies have shown that the agents are tolerated with some demonstration of single agent efficacy. Because efficacy is expected when the agents are used with conventional chemotherapeutic drugs or radiation, the results of Phase II combination studies are eagerly awaited.

This article has been cited by other articles:

				D. Zhao, E. Richer, P. P. Antich, and R. P. Mason Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI FASEB J, July 1, 2008; 22(7): 2445 - 2451. [Abstract] [Full Text] [PDF]

				A. Van Langendonckt, J. Donnez, S. Defrere, G. A.J. Dunselman, and P. G. Groothuis Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises Mol. Hum. Reprod., May 1, 2008; 14(5): 259 - 268. [Abstract] [Full Text] [PDF]

				M. H. A. M. Fens, E. Mastrobattista, A. M. de Graaff, F. M. Flesch, A. Ultee, J. T. Rasmussen, G. Molema, G. Storm, and R. M. Schiffelers Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells Blood, May 1, 2008; 111(9): 4542 - 4550. [Abstract] [Full Text] [PDF]

				S. Gould, F. R. Westwood, J. O. Curwen, S. E. Ashton, D. W. Roberts, S. C. Lovick, and A. J. Ryan Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in Rats J Natl Cancer Inst, November 21, 2007; 99(22): 1724 - 1728. [Abstract] [Full Text] [PDF]

				J.-N. Rybak, C. Roesli, M. Kaspar, A. Villa, and D. Neri The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases Cancer Res., November 15, 2007; 67(22): 10948 - 10957. [Abstract] [Full Text] [PDF]

				S.-C. J. Yeung, M. She, H. Yang, J. Pan, L. Sun, and D. Chaplin Combination Chemotherapy Including Combretastatin A4 Phosphate and Paclitaxel Is Effective against Anaplastic Thyroid Cancer in a Nude Mouse Xenograft Model J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2902 - 2909. [Abstract] [Full Text] [PDF]

				M. I. Milowsky, D. M. Nanus, L. Kostakoglu, C. E. Sheehan, S. Vallabhajosula, S. J. Goldsmith, J. S. Ross, and N. H. Bander Vascular Targeted Therapy With Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors J. Clin. Oncol., February 10, 2007; 25(5): 540 - 547. [Abstract] [Full Text] [PDF]

				M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]

				H. W. Salmon and D. W. Siemann Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity. Clin. Cancer Res., July 1, 2006; 12(13): 4090 - 4094. [Abstract] [Full Text] [PDF]

				P. Martinive, J. De Wever, C. Bouzin, C. Baudelet, P. Sonveaux, V. Gregoire, B. Gallez, and O. Feron Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol. Cancer Ther., June 1, 2006; 5(6): 1620 - 1627. [Abstract] [Full Text] [PDF]

				J. V. Skliarenko, S. J. Lunt, M. L. Gordon, A. Vitkin, M. Milosevic, and R. P. Hill Effects of the Vascular Disrupting Agent ZD6126 on Interstitial Fluid Pressure and Cell Survival in Tumors Cancer Res., February 15, 2006; 66(4): 2074 - 2080. [Abstract] [Full Text] [PDF]

				R. Ansiaux, C. Baudelet, G. O. Cron, J. Segers, C. Dessy, P. Martinive, J. De Wever, J. Verrax, V. Wauthier, N. Beghein, et al. Botulinum Toxin Potentiates Cancer Radiotherapy and Chemotherapy Clin. Cancer Res., February 15, 2006; 12(4): 1276 - 1283. [Abstract] [Full Text] [PDF]

				P. A. Campochiaro and the First ARVO/Pfizer Institute Working Group Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 462 - 474. [Full Text] [PDF]

				H. Akiyama, K. A. Mohamedali, R. L. e Silva, S. Kachi, J. Shen, C. Hatara, N. Umeda, S. F. Hackett, S. Aslam, M. Krause, et al. Vascular Targeting of Ocular Neovascularization with a Vascular Endothelial Growth Factor121/Gelonin Chimeric Protein Mol. Pharmacol., December 1, 2005; 68(6): 1543 - 1550. [Abstract] [Full Text] [PDF]

				S. Ferretti, P. R. Allegrini, T. O'Reilly, C. Schnell, M. Stumm, M. Wartmann, J. Wood, and P. M.J. McSheehy Patupilone Induced Vascular Disruption in Orthotopic Rodent Tumor Models Detected by Magnetic Resonance Imaging and Interstitial Fluid Pressure Clin. Cancer Res., November 1, 2005; 11(21): 7773 - 7784. [Abstract] [Full Text] [PDF]

				A. Shrivastava, M.A. von Wronski, A.K. Sato, D.T. Dransfield, D. Sexton, N. Bogdan, R. Pillai, P. Nanjappan, B. Song, E. Marinelli, et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases Protein Eng. Des. Sel., September 1, 2005; 18(9): 417 - 424. [Abstract] [Full Text] [PDF]

				G. Keller, A. V. Schally, K. Groot, G. L. Toller, A. Havt, F. Koster, P. Armatis, G. Halmos, M. Zarandi, J. L. Varga, et al. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone PNAS, July 26, 2005; 102(30): 10628 - 10633. [Abstract] [Full Text] [PDF]

				K. C. Graham, L. A. Wirtzfeld, L. T. MacKenzie, C. O. Postenka, A. C. Groom, I. C. MacDonald, A. Fenster, J. C. Lacefield, and A. F. Chambers Three-dimensional High-Frequency Ultrasound Imaging for Longitudinal Evaluation of Liver Metastases in Preclinical Models Cancer Res., June 15, 2005; 65(12): 5231 - 5237. [Abstract] [Full Text] [PDF]

				M. Narazaki and G. Tosato Targeting Coagulation to the Tumor Microvasculature: Perspectives and Therapeutic Implications From Preclinical Studies J Natl Cancer Inst, May 18, 2005; 97(10): 705 - 707. [Full Text] [PDF]

				X. Huang, M. Bennett, and P. E. Thorpe A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice Cancer Res., May 15, 2005; 65(10): 4408 - 4416. [Abstract] [Full Text] [PDF]

				L. D. McPhail, Y.-L. Chung, B. Madhu, S. Clark, J. R. Griffiths, L. R. Kelland, and S. P. Robinson Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy Clin. Cancer Res., May 15, 2005; 11(10): 3705 - 3713. [Abstract] [Full Text] [PDF]

				M. Belleri, D. Ribatti, S. Nicoli, F. Cotelli, L. Forti, V. Vannini, L. A. Stivala, and M. Presta Antiangiogenic and Vascular-Targeting Activity of the Microtubule-Destabilizing trans-Resveratrol Derivative 3,5,4'-Trimethoxystilbene Mol. Pharmacol., May 1, 2005; 67(5): 1451 - 1459. [Abstract] [Full Text] [PDF]

				G. Taraboletti, G. Micheletti, R. Dossi, P. Borsotti, M. Martinelli, F. Fiordaliso, A. J. Ryan, and R. Giavazzi Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies Clin. Cancer Res., April 1, 2005; 11(7): 2720 - 2726. [Abstract] [Full Text] [PDF]

				Y.-J. Zhou, S.-Q. Wang, J. Zhang, W. Zhang, F. Bi, Z.-G. Guo, B.-S. Ding, P. Kumar, J.-N. Liu, and X.-Y. Tan A novel method to isolate and map endothelial membrane proteins from pulmonary vasculature Am J Physiol Cell Physiol, April 1, 2005; 288(4): C950 - C956. [Abstract] [Full Text] [PDF]

				M. Murga, O. Fernandez-Capetillo, and G. Tosato Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2 Blood, March 1, 2005; 105(5): 1992 - 1999. [Abstract] [Full Text] [PDF]

				A. V. Roschke, S. Lababidi, G. Tonon, K. S. Gehlhaus, K. Bussey, J. N. Weinstein, and I. R. Kirsch Karyotypic "state" as a potential determinant for anticancer drug discovery PNAS, February 22, 2005; 102(8): 2964 - 2969. [Abstract] [Full Text] [PDF]

				S. Ran, J. He, X. Huang, M. Soares, D. Scothorn, and P. E. Thorpe Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice Clin. Cancer Res., February 15, 2005; 11(4): 1551 - 1562. [Abstract] [Full Text] [PDF]

				D. W. Siemann, M. C. Bibby, G. G. Dark, A. P. Dicker, F. A.L.M. Eskens, M. R. Horsman, D. Marme, and P. M. LoRusso Differentiation and Definition of Vascular-Targeted Therapies Clin. Cancer Res., January 15, 2005; 11(2): 416 - 420. [Abstract] [Full Text] [PDF]

				R. K. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science, January 7, 2005; 307(5706): 58 - 62. [Abstract] [Full Text] [PDF]

				Y. S. Jhanwar and C. Divgi Current Status of Therapy of Solid Tumors J. Nucl. Med., January 1, 2005; 46(1_suppl): 141S - 150S. [Abstract] [Full Text] [PDF]